Multigene Testing in Localized Prostate Cancer

Restricted access

Currently, there are several commercially available multigene tests for risk stratification in prostate cancer. These tests have been validated retrospectively; however, prospective studies are needed to fully establish their clinical roles. In some cases, molecular studies may add value, and updated NCCN Guidelines recommend “consideration” of molecular tests under certain circumstances, such as to help ascertain the likelihood of death from conservative management, of biochemical progression after radical prostatectomy or external-beam therapy, and of developing metastasis after radical prostatectomy or salvage radiotherapy.

Correspondence: Ashley E. Ross, MD, PhD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 725 North Wolfe Street, Baltimore, MD 21205. E-mail: aross2@jhmi.edu
  • 1.

    Cuzick J, Swanson GP, Fisher G. Prognostic value of an FRNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer. Lancet Oncol 2011:12:2119.

    • Search Google Scholar
    • Export Citation
  • 2.

    Cooperberg MR, Simko JP, Cowan JE. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31:14281434.

    • Search Google Scholar
    • Export Citation
  • 3.

    Bishoff JT, Freedland SJ, Gerber L. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 2014;192:409414.

    • Search Google Scholar
    • Export Citation
  • 4.

    Freedland SJ, Gerber L, Reid J. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation. Int J Radiat Oncol Biol Phys 2013;86:848853.

    • Search Google Scholar
    • Export Citation
  • 5.

    Cuzick J, Stone S, Fisher G. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer 2015;113:382389.

    • Search Google Scholar
    • Export Citation
  • 6.

    Brand TC, Zhang N, Crager MR. Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene Genomic Prostate Score. Urology 2016;89:6975.

    • Search Google Scholar
    • Export Citation
  • 7.

    Blume-Jensen P, Berman DM, Rimm DL. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res 2015;21:25912600.

    • Search Google Scholar
    • Export Citation
  • 8.

    Karnes RJ, Bergstrath EJ, Davicioni E. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013;190:20472053.

    • Search Google Scholar
    • Export Citation
  • 9.

    Ross AE, Johnson MH, Yousefi K. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol 2016;69:157165.

    • Search Google Scholar
    • Export Citation
  • 10.

    Klein EA, Yousefi K, Haddad Z. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol 2015;67:778786.

    • Search Google Scholar
    • Export Citation
  • 11.

    Cooperberg MR, Davicioni E, Crisan A. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2015;67:326333.

    • Search Google Scholar
    • Export Citation
  • 12.

    Freedland SJ, Choeurng V, Howard L. Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy [published online ahead of print January 21, 2016]. Eur Urol, doi: 10.1016.j.eururo.2016.01.008.

    • Search Google Scholar
    • Export Citation
  • 13.

    Alam R, Carter HB, Landis P. Conditional probability of reclassification in an active surveillance program of prostate cancer. J Urol 2015;193:19501955.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 68 54 16
PDF Downloads 22 17 1
EPUB Downloads 0 0 0